Human amniotic membrane transplantation for macular hole-associated retinal detachment: A systematic review of outcomes in refractory and complex cases
In brief
Amniotic membrane reattached retinas in 92% to 100% of reported cases
Across 18 studies covering about 196 eyes with macular hole-associated retinal detachment, amniotic membrane transplantation was followed by retinal reattachment in 91.7% to 100% of cases and hole closure in 70% to 100%. Vision generally improved, but graft movement or contraction occurred in some cases; without randomized trials, its benefits over other surgical options remain uncertain.
- Journal
- Survey of ophthalmology (Q1)
- Published
- 9 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Nicola Claudio D'Onofrio, Federica Mirabella, Giuseppe Mirabella, Alessandra Scampoli, Antonio Baldascino, Stanislao Rizzo, et al.
- PMID
- 43003356
- DOI
- 10.1016/j.survophthal.2026.11.009
Why clinicians should know about it
- Picked for Ophthalmology (top studies of the week, 15 November 2026): Clinical retinal surgery review reports anatomical and visual outcomes
Abstract
We systematically review the anatomical and functional outcomes of human amniotic membrane (hAM) transplantation in the surgical management of macular hole-associated retinal detachment (MHRD). We conducted systematic search of PubMed, Scopus, and Cochrane CENTRAL for studies published from January, 2018, to March, 2026, reporting the use of hAM for MHRD. Primary outcomes included macular hole (MH) closure rate, retinal reattachment rate, and best-corrected visual acuity (BCVA) change. Risk of bias was assessed using JBI Critical Appraisal Checklists. The review followed PRISMA 2020 guidelines. We included 18 studies encompassing approximately 196 eyes (12 case series, 3 case reports, 2 comparative studies, 1 prospective comparative). No randomized controlled trials were identified. The overall MH closure rate ranged from 70% to 100% across studies, with most series reporting closure rates above 90%. Retinal reattachment was achieved in 91.7% to 100% of cases. Mean BCVA improved significantly in the majority of studies, with the greatest improvement observed in the retinal detachment subgroup. Cryopreserved hAM with subretinal placement was the most commonly used technique, although epiretinal placement of lyophilized membranes showed comparable results. Graft dislocation or contraction occurred in 0% to 25% of cases. No major adverse events such as endophthalmitis, rejection, or significant inflammation were reported. We concluded that hAM transplantation appears to be a safe and effective rescue option for MHRD, particularly in cases where conventional approaches such as inverted ILM flap have failed or are not feasible, including recurrent MHRD in highly myopic eyes, cases with unavailable residual ILM, and complex retinal detachments with limited surgical alternatives. The evidence is limited to case series and case reports; randomized controlled trials are warranted to establish the comparative efficacy of hAM versus alternative techniques.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.